This is a retrospective observational study to describe the sociodemographic and clinical characteristics of patients diagnosed with non-valvular atrial fibrillation (NVAF) at risk of stroke or systemic embolism, who at least three months ago changed their anticoagulant therapy, due to any clinical situation, and are currently on treatment with a direct oral anticoagulant (DOAC)
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Age
Timeframe: At baseline visit
Gender
Timeframe: At baseline visit
Race
Timeframe: At baseline visit
Composite of relevant cardiovascular events: stroke, TIA, systemic embolism, bleeding
Timeframe: At baseline visit
Composite number of participants with comorbidities: hypertension, heart failure, diabetes mellitus, kidney failure, dyslipidemia
Timeframe: At baseline visit
Dose on the Non-Valvular Atrial Fibrillation treatment: relevant active substances
Timeframe: At baseline visit
Frequency on the Non-Valvular Atrial Fibrillation treatment: relevant active substances
Timeframe: At baseline visit
Duration on the Non-Valvular Atrial Fibrillation treatment: relevant active substances
Timeframe: At baseline visit
Concomitant treatments: therapy group of relevant active substances
Timeframe: At baseline visit
Risk of thromboembolic event based on the CHADS2 score
Timeframe: At baseline visit
Risk of thromboembolic event based on the CHA2DS2-VASc score
Timeframe: At baseline visit
Risk of bleeding based on the HAS-BLED score
Timeframe: At baseline visit